Loading...
Please wait, while we are loading the content...
Similar Documents
Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study.
| Content Provider | Europe PMC |
|---|---|
| Author | Kang, Weirong Svirskis, Darren Sarojini, Vijayalekshmi McGregor, Ailsa L. Bevitt, Joseph Wu, Zimei |
| Copyright Year | 2017 |
| Abstract | The efficacy of boron neutron capture therapy depends on the selective delivery of 10B to the target. Integrins αvβ3 are transmembrane receptors over-expressed in both glioblastoma cells and its neovasculature. In this study, a novel approach to dual-target glioblastoma vasculature and tumor cells was investigated. Liposomes (124 nm) were conjugated with a αvβ3 ligand, cyclic arginine-glycine-aspartic acid-tyrosine-cysteine peptide (c(RGDyC)-LP) (1% molar ratio) through thiol-maleimide coupling. Expression of αvβ3 in glioblastoma cells (U87) and human umbilical vein endothelial cells (HUVEC), representing tumor angiogenesis, was determined using Western Blotting with other cells as references. The results showed that both U87 and HUVEC had stronger expression of αvβ3 than other cell types, and the degree of cellular uptake of c(RGDyC)-LP correlated with the αvβ3-expression levels of the cells. In contrast, control liposomes without c(RGDyC) showed little cellular uptake, regardless of cell type. In an in vitro boron neutron capture therapy study, the c(RGDyC)-LP containing sodium borocaptate generated more rapid and significant lethal effects to both U87 and HUVEC than the control liposomes and drug solution. Interestingly, neutron irradiated U87 and HUVEC showed different types of subsequent cell death. In conclusion, this study has demonstrated the potential of a new dual-targeting strategy using c(RGDyC)-LP to improve boron neutron capture therapy for glioblastoma. |
| Journal | Oncotarget |
| Volume Number | 8 |
| PubMed Central reference number | PMC5482681 |
| Issue Number | 22 |
| PubMed reference number | 28402271 |
| e-ISSN | 19492553 |
| DOI | 10.18632/oncotarget.16625 |
| Language | English |
| Publisher | Impact Journals LLC |
| Publisher Date | 2017-05-01 |
| Access Restriction | Open |
| Rights License | This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. Copyright: © 2017 Kang et al. |
| Subject Keyword | boron neutron capture therapy (BNCT) dual-targeting drug delivery glioblastomas Integrin αv and β3 cyclic RGD peptides |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
